Flow Cytometry 2012: Market Needs, Emerging Developments and Future Use
Flow Cytometry 2012: Market Needs, Emerging Developmentsand Future UseReport Details:Published:September 2012No. of Pages:Price: Single User License – US$2355Biopharm Reports has carried out a study of market needs in the flow cytometry field. This studyexamined current techniques and applications, end-users’ plans for using flow cytometry over thenext three years, as well as preferred products, purchasing and new developments. The findingsof this study provide valuable support to developers and vendors operating in this field.This study involved the participation of 260 experienced flow cytometry users and decision-makersin 53 countries. It investigated current and future applications, current and future purchasing plans,research vs. clinical use across the study, new and emerging applications, end-users’ principalflow cytometers and their strengths and weaknesses, current annual and future budgets, budgetbreakdown, main consumables, challenges, innovation, use of analysis (offline) software, qualitycontrol guidelines, sample preparation, and other areas. As part of this study, end-users provideddetails of their anticipated purchases from suppliers in this field, over the period 2012 – 2015.Key Findings•Routine use: Use of flow cytometry (FC) by end-users for routine (developed and validated) FC tests, the development or validation of FC tests and for qualitative discovery using FC methods.•Companies: End-users purchases/use of FC systems from more than 25 companies and their anticipated use of these systems over the next three years, each ranked according to their competitive position•General and clinical: FC use (defined in this study description) by research scientists/research managers and clinicians/physicians•FC methods: Current use of more than 25 FC general applications and 15 clinical applications by end-users and the anticipated use of these applications over the next three years, each ranked according to their competitive position.•Main applications: End-users’ two main applications of FC, each ranked according to their competitive position.•New applications: New FC applications used by end-users in the last three years, each ranked according to their competitive position.•Emerging applications: Emerging applications of FC, indicated by end-users.•Main flow cytometer: End-users’ main flow cytometer, each ranked according to their competitive position.
•Strengths: End-users’ disclosures of the strengths of their main flow cytometer, each ranked according to their competitive position.•Weaknesses: End-users’ disclosures of the weaknesses of their main flow cytometer, each ranked according to their competitive position.•Current financial budgets: End-users’ annual financial budgets for FC studies.•Current budget breakdown: The breakdown of end-users’ FC financial budgets in nine key areas, relating to their current expenditure on FC products and activities.•Future financial budgets: End-users’ anticipated financial budget changes (percentage increases or decrease, a measure of the financial growth of this field) over the next three years, relating to their FC activities.•Consumables: End-users’ top consumables, associated with their FC activities.•Quality control guidelines: End-users’ adherence to quality control guidelines or procedures, relating to the conduct of FC studies.•Cost per sample: End-users’ disclosures on the costs per sample analysed, using FC.•Current challenges: End-users’ disclosures on the parameters or measurements that present the greatest technical challenges to FC analysis, together with the associated sample types (matrices), associated FC methods and underlying reasons.•Innovation: End-users’ disclosures relating to 11 key areas of required innovation in the FC field, each ranked (on a scale of 1 to 10) according to their importance.•Biomarkers: End-users’ application of FC methods for the study of disease biomarkers, namely molecular types and their clinical utilities.•Organisations: End-users organisations include clinics or hospitals, government bodies, large international companies, research institutes, small and medium sized companies, universities and veterinary centres.•Fields: End-users professional fields include biotechnology, chemicals, clinical or hospital, defence, energy, environmental, food and drink, forensics, geology, government, healthcare, natural products, pharmaceuticals, research institutes, security and universities.•Therapeutic areas: End-users’ FC activities in terms of their general therapeutic area (20 different areas covered), including the main diseases to which their work in this field relates.•Software: End-users’ disclosures on their preferred analysis (off-line) software, associated with FC studies.•Purpose: End-users’ underlying reasons for using FC analysis across 17 major fields (biotechnology, chemicals, clinical or hospital, defence, diagnostics (medical), energy, environmental, food and drink, forensics, geology, government, healthcare, natural products, pharmaceuticals, research institutes, security, university), each ranked according to their relative importance.•Study samples: Study sample types analysed by end-users using FC methods, each ranked according to their relative importance.•Sample preparation: The use of sample preparation methods by end-users for FC studies, each ranked according to their importance.
Get your copy of this report @http://www.reportsnreports.com/reports/191887-flow-cytometry-2012-market-needs-emerging-developments-and-future-use.htmlMajor points covered in Table of Contents of this report includeTable of Contents1 Introduction2 Study ParticipantsInvestigated: Participants’ countries, regions, organisation types, departments and professionalfields. Figures and/or tables are also presented.2.1 This chapter2.2 Countries2.3 Regions2.4 Organisation types2.5 Departments2.6 Fields2.7 DiscussionFields:BiotechnologyChemicalsClinical or HospitalDefenseDiagnostics (Medical)EnergyEnvironmentalFood and DrinkForensicsGeologyGovernmentHealthcareNatural ProductsPharmaceuticalsResearch InstituteSecurityUniversityOtherOrganisation TypesUniversityResearch InstituteSmall or Medium Sized CompanyLarge International CompanyClinic or HospitalGovernment Organisation
Veterinary OrganisationOther3 Purpose of Flow CytometryInvestigated: Participants’ purpose or reasons for using flow cytometry in their specified fields (seeFields, Chapter 2). The purposes or reasons for using flow cytometry, which may be unique toparticular fields, were taken into account. Example: The purpose or reasons for using flowcytometry in the “Clinical or Hospital” field were clinical research, routine diagnostics, routinescreening, clinical trials, treatment monitoring, diagnostics research, disease research, drug R&D,drug targets, pathology, toxicology and other. Figures and/or tables are also presented.3.1 This chapter3.2 Purpose3.3 Discussion4 Main ActivitiesInvestigated: The professional roles of study participants, namely as researchers or researchmanagers, clinicians or physicians. Figures and/or tables are also presented.4.1 This chapter4.2 Researchers or Research Managers4.3 Clinicians or Physicians4.4 Discussion5 Flow Cytometric TestsInvestigated: Participants’ use of flow cytometry in one of three areas, namely i) the running ofroutine cytometric tests ii) the developing of new cytometric tests or iii) qualitative (cytometric)discovery. Figures and/or tables are also presented.5.1 This chapter5.2 Flow cytometric tests5.3 Discussion6 Therapeutic AreaInvestigated: The therapeutic area(s) in which study participants work, relating to their use of flowcytometry. Figures and/or tables are also presented.6.1 This chapter6.2 Therapeutic Areas6.3 DiscussionTherapeutic AreasArthritisAutoimmune DiseasesBone MetabolismCancerCardiovascularCentral Nervous SystemDentistryDermatologyEndocrine
GastrointestinalGenito-urinary SystemHaematologyInfectionsInflammationMetabolic DisordersMusculoskeletal DisordersNutritionObstetrics and GynaecologyOphthalmologyPainPsychiatryRespiratorySkinOther7 Main DiseasesInvestigated: The main disease areas in which study participants work, relating to their use of flowcytometry. Figures and/or tables are also presented.7.1 This chapter7.2 Disease areas7.3 Discussion8 SamplesInvestigated: The sample types analysed by study participants, using flow cytometry. Figuresand/or tables are also presented.8.1 This chapter8.2 Samples8.3 DiscussionSample TypesAnimal tissuesCerebrospinal fluidBone MarrowHuman tissuesMicrobiological materialsPathology samplesPlant materialsLymphSalivaUrineWhole bloodOther9 General ApplicationsInvestigated: Participants current and anticipated future use (2012 – 2015) of flow cytometry, in
respect of 26 specified general applications, or others. Figures and/or tables are also presented.9.1 This chapter9.2 Current general applications9.3 Anticipated future general applications9.4 DiscussionGeneral Application AreasADME StudiesToxicity studiesApoptosisBacteria analysisBacterial membrane potentialBead-based immunoassaysCell adherenceCell cycleCell signallingCell sortingCellular kineticsDNA and RNA contentProtein expressionFRETImmunophenotypingIntracellular calcium fluxMembrane asymmetryMitochondrial membrane potentialMulticolour Flow CytometryNecrosisOrganelle functionProtein expression and localizationRare event analysisStem cell researchT Cell immunologyTransgenic products (e.g. GFP)Other10 Clinical ApplicationsInvestigated: Participants current and anticipated future use (2012 – 2015) of flow cytometry, inrespect of 19 specified clinical applications, or others. Figures and/or tables are also presented.10.1 This chapter10.2 Current clinical applications10.3 Anticipated future clinical applications10.4 DiscussionClinical ApplicationsCell counting
Cell functionCell pigmentsCell ProliferationCell surface antigens (e.g. CD markers)Cell viabilityDiagnosis of haematologic malignanciesDNA ploidyEnzymatic activityInfectious diseasesIntracellular antigensMinimal residual diseaseMonitoring AIDS patientsMonitoring chemotherapyMultidrug Resistance (MDR)Organ or stem-cell transplantationPlatelet function analysisTransfusion medicineVolume and morphology of cellsOther11 Main ApplicationsInvestigated: Participants main flow cytometry applications. Figures and/or tables are alsopresented.11.1 This chapter11.2 Main applications11.3 Discussion12 New ApplicationsInvestigated: New flow cytometry applications that study participants anticipate they will be usingin the next three years. Figures and/or tables are also presented.12.1 This chapter12.2 New applications12.3 Discussion13 Emerging ApplicationsInvestigated: Emerging flow cytometry applications that study participants believe offer promise intheir field. Figures and/or tables are also presented.13.1 This chapter13.2 Emerging applications13.3 Discussion14 SuppliersInvestigated: Participants current and an anticipated future (2012 – 2015) flow cytometry suppliersor vendors, in respect of 20 specified companies, or others. Figures and/or tables are alsopresented.14.1 This chapter
14.2 Current suppliers14.3 Future suppliers14.4 DiscussionSuppliersAmnis (Millipore)Apogee FlowApplied BioscienceBDBeckman CoulterBioCytexBio-RadCytonomeSTDVS SciencesiCyt (Sony)IntelliCytLife TechnologiesLuminexMiltenyiPartecPointCareStratedigmSysmexTTP LabTechUnion BiometricaOther15 Main Flow Cytometer, Strengths and WeaknessesInvestigated: Participants main flow cytometer, in terms of their most frequently used system,together with their strengths and weaknesses. Figures and/or tables are also presented.15.1 This chapter15.2 Main flow cytometer15.3 Discussion16 Reagents and AssaysInvestigated: Participants two main suppliers of reagents and assays for use in flow cytometry.Figures and/or tables are also presented.16.1 This Chapter16.2 Reagents and assays16.3 Discussion17 Sample PreparationInvestigated: Sample preparation methods used by participants, for flow cytometry studies.Figures and/or tables are also presented.10.1 This Chapter10.2 Sample Preparation
10.3 Discussion18 SoftwareInvestigated: Participants use of data analysis (offline) software, for flow cytometry studies.Figures and/or tables are also presented.18.1 This Chapter18.2 Software18.3 Discussion19 ChallengesInvestigated: The measurements or parameters that present the greatest technical challenge tostudy participants, relating to their use of flow cytometry. The parameter, sample type (matrix) andcytometer used were indicated, together with the main underlying reasons. Figures and/or tablesare also presented.19.1 This chapter19.2 Parameters19.3 Sample type (matrix)19.4 Flow cytometer19.5 Reasons19.6 Discussion20 InnovationInvestigated: Participants views on areas of required innovation (ranked on a scale of 1 to 10,where 1 is the least important and 10 is the most important), in respect of 10 specified areas, orothers. Figures and/or tables are also presented.20.1 This chapter20.2 Innovation20.3 DiscussionInnovation AreasAutomationDetectorsFluidicsLasers/Light SourcesOffline (Analysis) softwareOnline Data handlingQualitative selectivityQuantitative sensitivityReagentsSample preparationOther21 Disease BiomarkersInvestigated: Participants two main biomarkers investigated or measured using flow cytometry andtheir applications in terms of nine clinical utilities. Figures and/or tables are also presented.21.1 This chapter21.2 Biomarkers
21.3 Clinical utility21.4 DiscussionClinical UtilitiesDisease prognosisDisease susceptibility or riskDisease stage or severityDrug discoveryEarly detection of diseaseClinical trial endpointGuiding treatmentResponse to therapySafety or toxicity factorsOther22 Flow Cytometry Expenditure and BudgetsInvestigated: Financial expenditure and budgets relating to the current and future use of flowcytometry, including end-users’ current annual budgets across specified ranges (see CurrentAnnual financial budgets), the average flow cytometry analysis costs/sample across specifiedranges (see Flow Cytometry Costs per Sample), budget breakdown across nine specified areas(see Budget Breakdown Areas) and overall annual financial budget for flow cytometry (eitherincreasing or decreasing in % terms), over the next three years (see Future Budget Changes).Figures and/or tables are also presented.22.1 This chapter22.2 Annual budgets22.3 Costs per sample22.4 Budget breakdown22.5 Future budget22.6 DiscussionCurrent Annual Financial Budgets<$1 k$1 - $2.5k$2.5 - $5k$5 - $10k$10 - $25k$25 - $50k$50 - $100k$100 - $250k$250 - $500k$500k - $1 million$1 million - $2.5 million$2.5 million - $5 million>$5 m
+40%+50%>+50%Increasing23 ConsumablesInvestigated: Participants two main consumables in terms of costs, that are directly associatedwith their use of flow cytometry. Figures and/or tables are also presented.23.1 This Chapter23.2 Consumables23.3 Discussion24 Quality ControlInvestigated: Quality control systems or procedures adhered to in the use of flow cytometry.Figures and/or tables are also presented.24.1 This chapter24.2 Quality control24.3 DiscussionContact: email@example.com for more information.